CeRéMAIA
French Reference Center for rare Auto-Inflammatory Diseases and Amyloidosis
     
Home
The CeRéMAIA
The sites
Diseases
Consultations
Education
Current studies
What's new
For patients
For professionals
International
The agenda
Contact
Useful links
 

What's new?

 

New clinical study

Pharmachild: This project of 3-10 years is to observe children with JIA during treatment with biological agents ± MTX.

JIR cohorte: This international cohort is dedicated to collect prospective and retrospective data on juvenile inflammatory diseases. With it's modular construction, this cohort is able to conduct multiple clinical research projects in parallel. The centers participating to the JIR cohorte are associated to the development of the projects and to the scientific publications.

New treatments

  • anti-IL1 (Canakinumab Ilaris®) has received marketing approval for use in the treatment of CAPS. Approval is now being sought for its use to treat systemic JIA/ Still’s disease.
    For more information
  • Anakinra receives approval for the treatment of CAPS syndromes from the age of 8 months
    For more information
 

Created by Florian Milhavet   |   Legal Info